Trial Profile
A phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of OTI-010 in subjects who receive HLA [human lymphocyte antigen]-identical sibling peripheral blood stem cell transplantation for hematologic malignancies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2015
Price :
$35
*
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Oct 2005 New trial record.